The monthly cost of Rinvoq can vary significantly, depending on factors such as insurance coverage, pharmacy, and the specific dosage and formulation prescribed. Without insurance, the list price for a 30-day supply of Rinvoq can range from approximately $6,000 to over $8,000 [1].
How much does Rinvoq cost with insurance?
With insurance, out-of-pocket costs for Rinvoq are typically lower. Co-pays can range from $10 to $100 per month for those with commercial insurance, though this can fluctuate. Patients with Medicare or Medicaid may have different coverage terms and costs [2].
Are there Rinvoq savings programs available?
AbbVie, the manufacturer of Rinvoq, offers a Rinvoq Complete Savings Card for eligible commercially insured patients. This program can reduce out-of-pocket costs to as low as $5 per month for a 12-month period, subject to certain terms and conditions [2]. Patient assistance programs may also be available for those who are uninsured or underinsured [3].
What is the difference between Rinvoq and other JAK inhibitors?
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. Other JAK inhibitors include Xeljanz (tofacitinib), Cibinqo (abrocitinib), and Jyseleca (filgotinib). While they share a similar mechanism of action, they differ in their specific JAK selectivity, approved indications, dosage forms, and potential side effect profiles. These differences can influence their clinical use and may also impact cost and insurance coverage [4].
When does the patent for Rinvoq expire?
Drug patent expiry dates are crucial for the potential entry of generic or biosimilar alternatives, which can lead to lower prices. Information regarding the specific patent expiration for Rinvoq (upadacitinib) can be accessed through resources that track pharmaceutical patents [5]. DrugPatentWatch.com provides a database of drug patents and their expiration timelines [5].